MMedXYNews
Ask AIHomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY News/Nephrology

Section

Nephrology

214 articles

Ask AI
All specialtiesNephrologynewsClinical UpdatesCardiologyOncology

Latest updates

Cardiology

Exploring the Link Between Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure Risk in Older Adults

Higher CKM syndrome stages correlate with adverse cardiac remodeling and increased heart failure risk in older adults, as shown in the ARIC Study.

Apr 28, 2026Sign in to read
Critical Care

Low-Calorie, Low-Protein Feeding in Shock: No Harm to Kidneys, NUTRIREA-3 Analysis Confirms

Early low-calorie and low-protein nutrition in critically ill patients with shock does not worsen renal outcomes compared to standard feeding, per NUTRIREA-3 post hoc analysis.

Apr 21, 2026Sign in to read
Gastroenterology

OCE-205 Signals a Potential New Direction for Hepatorenal Syndrome-AKI, with Tolerability at the Center

In a phase 2 randomized trial, OCE-205 improved HRS-AKI in more patients than placebo and showed no excess ischemic or respiratory toxicity, but the study was underpowered after early termination.

Apr 20, 2026
Diabetes & Endocrinology

Blood Pressure Variability Emerges as Independent Predictor of Kidney Disease Progression in Type 1 Diabetes, with African Caribbean Ethnicity as Key Risk Factor

A 14-year cohort study of 3,079 individuals with type 1 diabetes reveals that visit-to-visit blood pressure variability, particularly systolic blood pressure variability measured by average real variability, significantly predicts diabetic

Apr 5, 2026
Cardiology

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.

Mar 28, 2026
Clinical Updates

Deciphering Healthcare Costs in Type 2 Diabetes and Incident CKD: A Latent Class Trajectory Analysis in Hong Kong

A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.

Mar 26, 2026
Clinical Updates

Healthcare Economic Trajectories in Type 2 Diabetes and Incident CKD: Insights from a Latent Class Analysis in Hong Kong

This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.

Mar 22, 2026
Clinical Updates

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.

Mar 14, 2026
Emergency Medicine

Lower Mortality and Complication Rates for Solid-Organ Transplant Patients Treated at Specialized Transplant Centers for Emergency General Surgery

A large-scale retrospective study in Ontario indicates that solid-organ transplant recipients, particularly kidney transplant patients, experience significantly better outcomes for emergency general surgery conditions when treated at specia

Mar 13, 2026
Diabetes & Endocrinology

Decoding Glycemic Control in Dialysis: Why HbA1c and Glycated Albumin Require a Nuanced Approach

This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modali

Mar 10, 2026
Diabetes & Endocrinology

Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 Diabetes

A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the

Mar 7, 2026
Cardiology

Predicting Cardiovascular Outcomes in Fabry Disease: Identifying High-Risk Markers in the Modern Therapeutic Era

A multicenter study of 680 Fabry disease patients reveals that age, renal function, QRS duration, and left ventricular mass are critical independent predictors of major adverse cardiovascular events, highlighting persistent unmet needs desp

Mar 2, 2026Sign in to read
Cardiology

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I’m now fully focused on creating the JSON object. I’v

Feb 24, 2026
Internal Medicine

Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial

The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera

Feb 22, 2026
Hematology-Oncology

Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis

A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.

Feb 22, 2026
Nephrology

Selective TRPC6 Inhibition Emerges as a Novel Therapeutic Paradigm for Focal Segmental Glomerulosclerosis

A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, ma

Feb 16, 2026
Diabetes & Endocrinology

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.

Feb 9, 2026Sign in to read
Critical Care

Liberating the Kidney: Can a Conservative Dialysis Strategy Improve Recovery in AKI-D?

The LIBERATE-D randomized trial suggests that a conservative, indication-driven dialysis strategy may enhance kidney recovery and reduce treatment burden in stable patients with dialysis-requiring acute kidney injury compared to conventiona

Feb 9, 2026Sign in to read
Nephrology

Beyond the Plate: Mediterranean Lifestyle as a Potent Shield Against Chronic Kidney Disease

A large-scale prospective study from the UK Biobank reveals that a comprehensive Mediterranean lifestyle—integrating diet, physical activity, and social connectivity—significantly reduces the risk of incident chronic kidney disease by up to

Feb 5, 2026
Nephrology

Holistic Mediterranean Lifestyle Linked to 35 Percent Lower Risk of Incident Chronic Kidney Disease

A large-scale prospective study from the UK Biobank reveals that high adherence to a Mediterranean lifestyle, including diet, physical activity, and social habits, significantly reduces the risk of developing chronic kidney disease over an

Feb 4, 2026
Previous
5 / 11
1…34567…11
Next

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.